Norges Bank Merus N.V. Transaction History

Norges Bank

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$20.06 - $28.66 $1.21 Million - $1.73 Million	60,300 New	60,300 $1.66 Million
Q3 2023 Nov 13, 2024	BUY	$20.13 - $27.29 $1.21 Million - $1.65 Million	60,300 New	60,300 $1.42 Million
Q3 2023 Nov 13, 2023	SELL	$20.13 - $27.29 $1.51 Million - $2.05 Million	-75,000 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$18.33 - $27.18 $1.11 Million - $1.64 Million	60,300 New	60,300 $1.59 Million
Q2 2023 Aug 14, 2023	SELL	$18.33 - $27.18 $1.37 Million - $2.04 Million	-75,000 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$14.25 - $20.5 $859,275 - $1.24 Million	60,300 New	60,300 $1.11 Million
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $960,000 - $1.77 Million	75,000 New	75,000 $1.16 Million
Q3 2022 Nov 13, 2023	BUY	$18.64 - $28.93 $1.4 Million - $2.17 Million	75,000 New	75,000 $1.5 Million
Q2 2022 Aug 14, 2023	BUY	$13.98 - $29.25 $1.05 Million - $2.19 Million	75,000 New	75,000 $1.7 Million
Q1 2022 May 09, 2022	SELL	$23.58 - $30.91 $1.77 Million - $2.32 Million	-75,000 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$20.0 - $32.29 $1.5 Million - $2.42 Million	75,000 New	75,000 $2.39 Million
Q3 2017 Nov 07, 2017	SELL	$13.6 - $19.87 $154,944 - $226,378	-11,393 Closed	0 $0
Q2 2017 Jul 24, 2018	SELL	N/A	-8,607 Reduced 43.04%	11,393 $181,000
Q1 2017 May 11, 2018	SELL	N/A	-57,400 Reduced 74.16%	20,000 $488,000
Q3 2016 Nov 13, 2017	BUY	N/A	77,400	77,400 $0

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.